

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb20413</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Effect of Poly-Histidine Tag Position toward Inhibition Activity of Secretory Leukocyte Protease Inhibitor as Candidate for Material Wound Healing</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Munadziroh</surname><given-names>Elly</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ulfa</surname><given-names>Evi </given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Labiqah</surname><given-names>Amaliah</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Asmarani</surname><given-names>One</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Puspaningsih</surname><given-names>Ni Nyoman</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>12</volume>
      <issue>1</issue>
      <fpage>32</fpage>
      <lpage>36</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>1</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>4</month>
          <year>2019</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Background:&lt;/span&gt; The Secretory Leukocyte Protease Inhibitors (SLPI) has many biological functions including anti-bacterial, anti-fungal, anti-viral, anti-inflammatory, and immuno-modulatory. Previous studies have shown that gene-encoding human SLPI have successfully been expressed in &lt;em&gt;Escherichia coli (E. coli)&lt;/em&gt; with a C-terminal polyhistidine tag (His-tag). The aim of this research was to investigate the inhibition activity of N-terminal His-tag position (NSLPI) and C-terminal His-tag position (CSLPI). We hypothesized that a His-tag close to an active site SLPI domain may interfere with the inhibition activity of SLPIs.&lt;span style=&quot;font-size:2.0pt&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Methods:&lt;/span&gt; A NSLPI and CSLPI were constructed with polymerase chain reaction (PCR) amplification. The PCR products were then ligated into pET-30a plasmid and transformed into &lt;em&gt;E. coli &lt;/em&gt;TOP10. Recombinant plasmids were verified by using restriction analysis and nucleotide sequence analysis. pET-NSLPI and pET-CSLPI were then subcloned in &lt;em&gt;E. coli&lt;/em&gt; BL21(DE3) for its expression. The SLPI protein was expressed using Isopropyl &amp;beta;-D-1-thiogalactopyranoside induction (IPTG). The inhibition effect of both SLPI against Porcine Pancreatic Elastase (PPE) enzyme was tested using the N-succinyil-alanyl-L-alanyl-L-prolyl-L-phenylalanyl-4-nitroanalide (NPN) substrate.&lt;span style=&quot;font-size:2.0pt&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Results:&lt;/span&gt; The SLPI gene was successfully cloned and expressed in &lt;em&gt;E. coli&lt;/em&gt; BL21. Fusion proteins of NSLPI and CSLPI were generated with His-tag in the N-terminal and C-terminal position, respectively. The inhibition effect of NSLPI and CSLPI on PPE indicated that both SLPI were active. The inhibition activity of NSLPI was 66.7%, higher than CSLPI by 44.4%.&lt;span style=&quot;font-size:2.0pt&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Conclusion:&lt;/span&gt; The His-tag position on the C-terminal of SLPI reduced the inhibition activity of SLPI.&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
